BioTuesdays

Tag - Cantor Fitzgerald

Mereo Biopharma Logo

Cantor starts Mereo BioPharma at OW; PT $4

Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...

MindMed Logo

Cantor starts MindMed at OW; PT $3

Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...

Cantor starts Clever Leaves at OW; PT $4.50

Cantor Fitzgerald initiated coverage of Clever Leaves Holdings (NASDAQ:CLVR) with an “overweight” rating and $4.50 price target. The stock closed at 92 cents on July 27. “In relative terms, the stock offers better ‘pure...

biovie Logo

Cantor starts BioVie at OW; PT $7

Cantor Fitzgerald launched coverage of BioVie (NASDAQ:BIVI) with an “overweight” rating and $7 price target. The stock closed at $2.10 on July 21. BioVie is developing NE3107, an orally bioavailable anti-inflammatory...

Humanigen Logo

Cantor cuts Humanigen to neutral; PT to $2

Cantor Fitzgerald downgraded Humanigen (NASDAQ:HGEN) to “neutral” from “overweight” and slashed its price target to $2 from $30 after a failed COVID-19 study. The stock closed at $2.99 on July 12. The National Institute...

Neximmune Logo

Cantor assumes coverage of Neximmune at OW; PT $4

Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Neximmune (NASDAQ:NEXI) with an “overweight” rating and price target of $4. The stock closed at $1.61 on June 29. Neximmune is developing a novel T-cell...